Effets indésirables et abandon de l’induction de tolérance orale à l’arachide : expérience en vie réelle dans 3 centres pédiatriques (Lyon, Reims et Namur)

Pajno, 2018, EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy, Allergy, 73, 799, 10.1111/all.13319 Sicherer, 2010, US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up, J Allergy Clin Immunol, 125, 1322, 10.1016/j.jaci.2010.03.029 Rance, 2005, Prevalence and main characteristics of school children diagnosed with food allergies in France, Clin Exp Allergy, 35, 167, 10.1111/j.1365-2222.2005.02162.x Deschildre, 2016, Peanut-allergic patients in the MIRABEL survey: characteristics, allergists’ dietary advice and lessons from real life, Clin Exp Allergy, 46, 610, 10.1111/cea.12681 Pouessel, 2019, Food-related anaphylaxis fatalities: analysis of the Allergy Vigilance Network® database, Allergy, 74, 1193, 10.1111/all.13717 Greenhawt, 2016, Food allergy quality of life and living with food allergy, Curr Opin Allergy Clin Immunol, 16, 284, 10.1097/ACI.0000000000000271 Clark, 2009, Successful oral tolerance induction in severe peanut allergy, Allergy, 64, 1218, 10.1111/j.1398-9995.2009.01982.x Anagnostou, 2011, Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome: study of tolerance to oral peanut, Clin Exp Allergy, 41, 1273, 10.1111/j.1365-2222.2011.03699.x Varshney, 2011, A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response, J Allergy Clin Immunol, 127, 654, 10.1016/j.jaci.2010.12.1111 Anagnostou, 2014, Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial, Lancet, 383, 1297, 10.1016/S0140-6736(13)62301-6 Vickery, 2014, Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy, J Allergy Clin Immunol, 133, 10.1016/j.jaci.2013.11.007 The PALISADE Group of Clinical Investigators, 2018, AR101 oral immunotherapy for peanut allergy, N Engl J Med, 379, 1991, 10.1056/NEJMoa1812856 Chinthrajah, 2019, Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study, Lancet, 394, 1437, 10.1016/S0140-6736(19)31793-3 Ewan, 2001, Long-term prospective observational study of patients with peanut and nut allergy after participation in a management plan, Lancet, 357, 111, 10.1016/S0140-6736(00)03543-1 Wasserman, 2019, Real-world experience with peanut oral immunotherapy: lessons learned from 270 patients, J Allergy Clin Immunol Pract, 7, 10.1016/j.jaip.2018.05.023 Nachshon, 2018, Long-term outcome of peanut oral immunotherapy-Real-life experience, Pediatr Allergy Immunol, 29, 519, 10.1111/pai.12914 Soller, 2019, First real-world safety analysis of preschool peanut oral immunotherapy, J Allergy Clin Immunol Pract, 7, 10.1016/j.jaip.2019.04.010 Virkud, 2017, Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy, J Allergy Clin Immunol, 139, 10.1016/j.jaci.2016.07.030 Blumchen, 2019, Efficacy, safety, and quality of life in a multicenter, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in children with peanut allergy, J Allergy Clin Immunol Pract, 7, 10.1016/j.jaip.2018.10.048 Nagakura, 2018, Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan, Pediatr Allergy Immunol, 29, 512, 10.1111/pai.12898 Wasserman, 2014, Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions, J Allergy Clin Immunol Pract, 2, 10.1016/j.jaip.2013.10.001 Hofmann, 2009, Safety of a peanut oral immunotherapy protocol in children with peanut allergy, J Allergy Clin Immunol, 124, 10.1016/j.jaci.2009.03.045 Bird, 2018, Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial, J Allergy Clin Immunol Pract, 6, 10.1016/j.jaip.2017.09.016 Fauquert, 2018, Peanut gastrointestinal delivery oral immunotherapy in adolescents: results of the build-up phase of a randomized, double-blind, placebo-controlled trial (PITA study), Clin Exp Allergy, 48, 862, 10.1111/cea.13148 Feuille, 2018, Allergen-specific immunotherapies for food allergy, Allergy Asthma Immunol Res, 10, 189, 10.4168/aair.2018.10.3.189 Fernández-Rivas, 2019, ARTEMIS: a European, phase 3, randomised, double-blind, placebo-controlled trial of AR101 in peanut-allergic children and adolescents aged 4–17, Allergy, 74, 16 Itazawa, 2020, The severity of reaction after food challenges depends on the indication: a prospective multicenter study, Pediatr Allergy Immunol, 31, 167, 10.1111/pai.13140 Ruffner, 2018, Pediatric eosinophilic esophagitis: updates for the primary care setting, Curr Opin Pediatr, 30, 829, 10.1097/MOP.0000000000000698 Lucendo, 2014, Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis, Ann Allergy Asthma Immunol, 113, 624, 10.1016/j.anai.2014.08.004 Reier-Nilsen, 2019, Feasibility of desensitizing children highly allergic to peanut by high-dose oral immunotherapy, Allergy, 74, 337, 10.1111/all.13604 Jones, 2009, Clinical efficacy and immune regulation with peanut oral immunotherapy, J Allergy Clin Immunol, 124, 10.1016/j.jaci.2009.05.022 Vázquez-Ortiz, 2013, Safety and predictors of adverse events during oral immunotherapy for milk allergy: severity of reaction at oral challenge, specific IgE and prick test, Clin Exp Allergy, 43, 92, 10.1111/cea.12012 Howe, 2019, Changing patient mindsets about non-life-threatening symptoms during oral immunotherapy: a randomized clinical trial, J Allergy Clin Immunol Pract, 7, 1550, 10.1016/j.jaip.2019.01.022